Literature DB >> 12869085

Preliminary evaluation of an injectable anal sphincter bulking agent (Durasphere) in the management of faecal incontinence.

K Davis1, D Kumar, J Poloniecki.   

Abstract

BACKGROUND: It has been previously shown that 'bulking' of internal anal sphincter defects may provide an effective method to treat patients with faecal incontinence, but the benefit wears off with time. AIM: To assess the efficacy of a larger molecule, bulking agent (Durasphere) over the short- and long-term in patients with an internal anal sphincter defect refractory to conservative management. PATIENTS: Eighteen patients (nine male, nine female) with a mean age of 60 years were recruited. All patients had persistent faecal leakage/soiling.
METHODS: Durasphere was injected in the submucosal plane to restore anal canal symmetry. All patients had anorectal physiology, endoanal ultrasound, continence grading, patient satisfaction and quality of life scores assessed at 1, 3, 6 and 12 months.
RESULTS: The mean follow-up is 28.5 months. Changes from baseline were not statistically significant up to 6 months. At 12 months there was significant improvement in the continence grading (P=0.003), patient satisfaction (P=0.053) and all quality of life subscales: lifestyle (P=0.004), coping (P=0.011), depression (P=0.024) and embarrassment (P=0.059). Anorectal physiological parameters apart from the maximum tolerable rectal volume at 12 months (P=0.036) showed no significant improvement.
CONCLUSIONS: Anal sphincter bulking with Durasphere is safe and effective in the short term as well as the longer term. More importantly, there is no evidence of attenuation of effect over time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869085     DOI: 10.1046/j.1365-2036.2003.01668.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  19 in total

1.  Management of fecal incontinence.

Authors:  Adil E Bharucha
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-11

Review 2.  Combined urinary and faecal incontinence.

Authors:  Dharmesh S Kapoor; Ranee Thakar; Abdul H Sultan
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2005-02-24

Review 3.  Fecal incontinence: an up-to-date critical overview of surgical treatment options.

Authors:  Christophe Müller; Orlin Belyaev; Thomas Deska; Ansgar Chromik; Dirk Weyhe; Waldemar Uhl
Journal:  Langenbecks Arch Surg       Date:  2005-08-12       Impact factor: 3.445

4.  Fecal incontinence.

Authors:  Tracy Hull
Journal:  Clin Colon Rectal Surg       Date:  2007-05

Review 5.  Current status: new technologies for the treatment of patients with fecal incontinence.

Authors:  Andreas M Kaiser; Guy R Orangio; Massarat Zutshi; Suraj Alva; Tracy L Hull; Peter W Marcello; David A Margolin; Janice F Rafferty; W Donald Buie; Steven D Wexner
Journal:  Surg Endosc       Date:  2014-03-08       Impact factor: 4.584

6.  Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells.

Authors:  Levilester Salcedo; Marc Penn; Margot Damaser; Brian Balog; Massarat Zutshi
Journal:  Stem Cells Transl Med       Date:  2014-05-05       Impact factor: 6.940

Review 7.  Midterm outcomes of injectable bulking agents for fecal incontinence: a systematic review and meta-analysis.

Authors:  K D Hong; J S Kim; W B Ji; J W Um
Journal:  Tech Coloproctol       Date:  2017-03-01       Impact factor: 3.781

8.  Thinking outside the box: autotransplantation into GI sphincters.

Authors:  Peter J Kahrilas
Journal:  Gastrointest Endosc       Date:  2009-12       Impact factor: 9.427

9.  Comparison of bulking agents in the treatment of fecal incontinence: a prospective randomized clinical trial.

Authors:  O J Morris; S Smith; B Draganic
Journal:  Tech Coloproctol       Date:  2013-03-23       Impact factor: 3.781

10.  Injectable synthetic calcium hydroxylapatite ceramic microspheres (Coaptite) for passive fecal incontinence.

Authors:  E Ganio; F Marino; I Giani; A Realis Luc; G Clerico; E Novelli; M Trompetto
Journal:  Tech Coloproctol       Date:  2008-06-10       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.